Enanta Pharmaceuticals | ENTA - Current Assets


Enanta Pharmaceuticals reported $198.68M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
BioCryst Pharmaceuticals USD 484.68M 111.06M Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Gilead Sciences USD 12.53B 6.11B Jun/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Halozyme Therapeutics USD 933.02M 70.01M Jun/2026
Heron Therapeutics USD 229.84M 861K Jun/2026
Immunic USD 188.76M 165.89M Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
Insmed USD 1.63B 20.75M Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
J&J USD 59.77B 601M Jun/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Ligand Pharmaceuticals USD 1.46B 591.7M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Novartis USD 27.35B 744M Jun/2026
Novavax USD 771.1M 79.72M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sarepta Therapeutics USD 2.22B 86.05M Jun/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026